ONC — Oncolytics Biotech Income Statement
0.000.00%
Last trade - 00:00
- CA$100.10m
- CA$75.52m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20.7 | 25.5 | 26.2 | 26.9 | 33.8 |
Operating Profit | -20.7 | -25.5 | -26.2 | -26.9 | -33.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -33.1 | -22.5 | -26.3 | -24.8 | -27.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -33.1 | -22.5 | -26.3 | -24.8 | -27.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -33.1 | -22.5 | -26.3 | -24.8 | -27.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.1 | -22.5 | -26.3 | -24.8 | -27.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.5 | -0.558 | -0.492 | -0.428 | -0.41 |